Back to All Studies

Researchers recently developed a new cancer drug, eBAT, which improved post-diagnostic survival of dogs with a particularly deadly type of cancer called hemangiosarcoma. There has been virtually no gains in treatment for this disease since the introduction of surgery and adjunct chemotherapy in the 1980s, and this new drug is a promising step forward. eBAT uses proteins that fuel the growth of cancer cells as “baits” to deliver a lethal drug payload with high specificity to its target. eBAT is unique because it is designed to target cancer cells and the environment cancer cells take over. In this project, the researchers will define specifically how eBAT works to make the body inhospitable to cancer cells and determine the drug's potential to improve overall survival of dogs with other incurable cancers.

Study ID
D18CA-050
Study Status
Active
Start Date
12/01/2017
Grant amount awarded
$182,807
Grant recipient
University of Minnesota
Study country
United States
Investigator
Jaime F. Modiano, VMD, PhD
Study category
Cancer